Clinical evaluation of tuberculosis viability microscopy for assessing treatment response

Clinical Infectious Diseases

Volumn 60, Issue 8, 2015, Pages 1186-1195

  Datta, Sumona ^a,b   Sherman, Jonathan M ^a,c   Bravard, Marjory A ^a,c   Valencia, Teresa ^b   Gilman, Robert H ^d   Evans, Carlton A ^a,b  

^a UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c ASOCIACIÓN BENÉFICA PRISMA   (Peru)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

early bactericidal activity; fluorescein diacetate; multidrug resistant tuberculosis; viability stain; vital stain tuberculosis

Indexed keywords

AURAMINE; CAPREOMYCIN; CIPROFLOXACIN; ETHAMBUTOL; FLUORESCEIN DIACETATE; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL VIABILITY; BACTERIUM CULTURE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; HUMAN; LABORATORY TEST; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SPUTUM CYTODIAGNOSIS; TREATMENT RESPONSE; TUBERCULOSIS; ADULT; DRUG EFFECTS; DRUG MONITORING; EVALUATION STUDY; FEMALE; MALE; MICROBIAL VIABILITY; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MICROSCOPY; PROCEDURES; SPUTUM; TIME; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; BACTERIOLOGICAL TECHNIQUES; DRUG MONITORING; FEMALE; HUMANS; MALE; MICROBIAL VIABILITY; MICROSCOPY; SPUTUM; TIME FACTORS; TUBERCULOSIS; YOUNG ADULT;

EID: 84926616076     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu1153     Document Type: Article

References (40)

1. Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003; 167:1348-54.
2. Hobby GL, Holman AP, Iseman MD, Jones JM. Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis. Antimicrob Agents Chemother 1973; 4:94-104.
3. Davies GR, Brindle R, Khoo SH, Aarons LJ. Use of nonlinear mixedeffects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. Antimicrob Agents Chemother 2006; 50:3154-6.
4. World Health Organization. Global tuberculosis report 2013.
5. Grandjean L, Martin L, Gilman RH, et al. Tuberculosis diagnosis and multidrug resistance testing by direct sputum culture in selective broth without decontamination or centrifugation. J Clin Microbiol 2008; 46:2339-44.
6. Evans CA. GeneXpert-A game-changer for tuberculosis control?. PLoS Med 2011; 8:e1001064.
7. Friedrich SO, Rachow A, Saathoff E, et al. Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. Lancet Respir Med 2013; 1:462-70.
8. Desjardin LE, Perkins MD, Wolski K, et al. Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy. Am J Respir Crit Care Med 1999; 160:203-10.
9. Escombe AR, Oeser C, Gilman RH, et al. The detection of airborne transmission of tuberculosis from HIV-infected patients, using an in vivo air sampling model. Clin Infect Dis 2010; 44:1349-57.
10. Kvach J, Veras J. A fluorescent staining procedure for determining the viability of mycobacterial cells. Int J Lepr 1982; 50:183.
11. Katoch V, Katoch K, Ramanathan U, et al. Effect of chemotherapy on viability of Mycobacterium leprae as determined by ATP content, morphological index and FDA-EB flourescent staining. Int J Lepr 1989; 57:615-21.
12. Harada S, Numata N. Application of FDA/EB staining for the detection of viable or non-viable mycobacteria in clinical specimens. Kekkaku 1992; 67:113-7.
13. Kinomoto M. Development of slide-method to distinguish alive and dead mycobacteria by flourescent staining. Kekkaku 1999; 74:599-609.
14. Kirk SM, Schell RF, Moore AV, Callister SM, Mazurek GH. Flow cytometric testing of susceptibilities of Mycobacterium tuberculosis isolates to ethambutol, isoniazid, and rifampin in 24 hours. J Clin Microbiol 1998; 36:1568-73.
15. Moore AV, Kirk SM, Callister SM, Mazurek H, Schell RF, Mazurek GH. Safe determination of susceptibility of Mycobacterium tuberculosis to antimycobacterial agents by flow cytometry. J Clin Microbiol 1999; 37:479-83.
16. Norden MA, Kurzynski TA, Bownds SE, Callister SM, Schell RF. Rapid susceptibility testing of Mycobacterium tuberculosis (H37Ra) by flow cytometry. J Clin Microbiol 1995; 33:1231-7.
17. Bravard M, Sherman JM, Martin L, et al. Sputum vital stain microscopy to predict culture results and infectiousness. In: Proceedings of the 41st world annual Union Against Tuberculosis and Lung Diseases conference, Berlin, Germany, 2010; 13:S85. Available at: http://www.ifhad. org/publications/. Accessed 31 December 2014.
18. Sherman JM, Montoya R, Gilman RH, et al. Rapid monitoring of antituberculosis therapy using fluorescein diacetate microscopy a simple method to determine infectiousness andscreen for drug resistance. In: Proceedings of Royal Society of Tropical Medicine and Hygiene centennial conference; London, UK, 2007.
19. Sherman JM, Montoya R, Gilman RH, et al. Montoring anti-Tuberculosis therapy with fluorescein diacetate (FDA) microscopy rapidly determines infectiousness and screen for drug resistance. In: Proceedings of Medecins Sans Frontieres (MSF); Campaign for Access to Essential Medicines. Symposium on TB FIELD Diagnostics: 'Dying for a test;' Cape Town, South Africa, 2007. Available at: http://www.ifhad.org/ publications/. Accessed 31 December 2014.
20. Kawai V, Soto G, Gilman RH, et al. Tuberculosis mortality, drug resistance, and infectiousness in patents with and without HIV infection in Peru. Am J Trop Med Hyg 2010; 75:1027-33.
21. Ministerio de salud, Peru. Norma tecnica de salud para el control de la tuberculosis. Lima: Ministry of Health, 2006.
22. Rocha C, Montoya R, Zevallos K, et al. The Innovative Socio-economic Interventions Against Tuberculosis (ISIAT) project: an operational assessment. Int J Tuberc Lung Dis 2011; 15(suppl 2):S50-7.
23. Sherman JM, Tovar M, Gilman RH, et al. Using treatment failure to screen for MDRTB is associated with TB recurrence, death and transmission. In: Proceedings of 55th annual conference of the American Society of Tropical Medicine and Hygiene, Atlanta, GA, 2006: S312.
24. Datiko DG, Lindtjørn B. Tuberculosis recurrence in smear-positive patients cured under DOTS in southern Ethiopia: retrospective cohort study. BMC Public Health 2009; 9:348.
25. Kent PT. Public health mycobacteriology: a guide for the level III laboratory. Atlanta, GA: US Department of Health and Human Services, Public Health Service, Centers for Disease Control, 1985. Available at: https://catalyst.library.jhu.edu/catalog/bib-1853570. Accessed 12 February 2014.
26. Toman K. Toman's tuberculosis; case detection, treatment and monitoring-questions and answers. 2nd ed. Geneva, Switzerland: WHO, 2004.
27. Moore DAJ, Evans CAW, Gilman RH, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006; 355:1539-50.
28. Caviedes L, Lee TS, Gilman RH, et al. Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. The Tuberculosis Working Group in Peru. J Clin Microbiol 2000; 38:1203-8.
29. Caviedes L, Delgado J, Gilman RH. Tetrazolium microplate assay as a rapid and inexpensive colorimetric method for determination of antibiotic susceptibility of Mycobacterium tuberculosis. J Clin Microbiol 2002; 40:1873-4.
30. Moore DAJ, Caviedes L, Gilman RH, et al. Infrequent MODS TB culture cross-contamination in a high-burden resource-poor setting. Diagn Microbiol Infect Dis 2006; 56:35-43.
31. Chigutsa E, Patel K, Denti P, et al. A time-To-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture. Antimicrob Agents Chemother 2013; 57:789.
32. Bark CM, Gitta P, Johnson JL. Differences in EBA in the first two days of standard anti-Tuberculosis treatment in different geographic regions. Int J Tuberc Lung Dis 2003:1006-7.
33. Schramm B, Hewison C, Bonte L, et al. Field evaluation of a simple fluorescence method for detection of viable Mycobacterium tuberculosis in sputum specimens during treatment follow-up. J Clin Microbiol 2012; 50:2788-90.
34. Salim AH, Aung KJM, Hossain MA, Van Deun A. Early and rapid microscopy-based diagnosis of true treatment failure and MDR-TB. Int J Tuberc Lung Dis 2006; 10:1248-54.
35. Van Deun A, Maug AKJ, Hossain A, Gumusboga M, De Jong BC. Fluorescein diacetate vital staining allows earlier diagnosis of rifampicin-resistant tuberculosis. Int J Tuberc Lung Dis 2012; 16:1174-9.
36. Escombe AR, Moore DAJ, Gilman RH, et al. The infectiousness of tuberculosis patients coinfected with HIV. PLoS Med 2008; 5:e188.
37. World Health Organization. Fluorescent light-emitting diode (LED) microscopy for diagnosis of tuberculosis policy, 2011. Available at: http://www.who.int/tb/publications/2011/led-microscopy-diagnosis-9789241501613/en/. Accessed 20 February 2014.
38. Ramos E, Schumacher SG, Siedner M, et al. Optimizing tuberculosis testing for basic laboratories. Am J Trop Med Hyg 2010; 83:896-901.
39. Leung E, Minion J, Benedetti A, PaiM, Menzies D. Microcolony culture techniques for tuberculosis diagnosis : a systematic review. Int J Tuberc Lung Dis 2011; 16:16-23.
40. World Health Organization; Granich R, Binkin N, Jarvis W, Simone P, Rieder H. Guideline for the prevention of tuberculosis. Geneva, Switzerland: 1999: 31. Available at: http://www.who.int/tb/publications/who-Tb-99-269.pdf?ua=1. Accessed 19 May 2014.